PRNewsWire
17 Nov 2026, 13:50 UTC · 1h ago
Viatris Completes Acquisition of Pacira BioSciences
Impact · against what's priced in
Viatris has completed its acquisition of Pacira BioSciences, resulting in the delisting of PCRX. The deal provides an immediate liquidity event for Pacira shareholders and adds an incremental revenue run-rate of $90 million to $100 million for Viatris for the remainder of 2026.
- PCRX+0.80
No priced-in read yet
- In context
The company has been acquired for $36.50 per share in cash and will be delisted from the Nasdaq.
Read from the article alone

Search tags




